


BUILDING INNOVATIVE DRUG DISCOVERY AND DEVELOPMENT PARTNERSHIPS



Evotec is a leading drug discovery & development partnership company with an outstanding track record of delivering pre-clinical and clinical candidates. The combination of state-of-the-art capabilities, with a fully integrated interdisciplinary approach built on industry-leading drug discovery & development knowledge, maximizes the probability of successful drug discovery outcomes for our partners.

Seamless integration from idea to IND and beyond: World-class drug discovery & development, INDiGO and high-end CMC



Trusted partner through >20 years of delivery: Track record and current capacity of ~3000 scientists

STRONG TRACK RECORD

- ▶ >400 assay developments and high throughput screens
- ▶ >150 Hit-to-lead campaigns
- ▶ >300 patents with Evotec scientists as named inventors
- ▶ >100 preclinical candidates delivered
- ▶ ~20 INDs supported since 2016
- ▶ Decades of new technology development (FCS++, iPSCs, FMO, advanced proteomics, novel disruption of cell signalling ...)

GLOBALLY LEADING CURRENT STATE AND ACCELERATING

- ▶ ~50 high throughput screens per year, including BSL2, phenotypic, biophysics
- ▶ ~20 Hit-to-lead campaigns per year
- ▶ >40 concurrent integrated drug discovery projects in 2018
- ▶ >16 preclinical INDiGO packages ongoing
- ▶ 30 peer-reviewed publications in 2018
- ▶ Numerous continuations, new strategic partnerships, milestones, and clinical progressions announced in 2018

Some of the key factors that have enabled Evotec to deliver successful outcomes in multiple integrated projects in collaboration with and for our clients include:

- ▶ Experience in a broad range of target classes and diverse modalities, including both small and large molecules, peptides, biologics, natural products and macromolecules.
- ▶ Breadth and depth of our extensive disease biology, drug discovery and development expertise to deliver PDC/IND candidates for difficult targets against challenging timelines.
- ▶ Leading approaches to identify and expand hits, including MS-based, phenotypic, fragment-based, virtual and the application of machine learning and AI.
- ▶ High quality hypothesis driven and computationally enabled molecular design, coupled with fit-for-purpose screening cascades drive rapid DMTA cycles, in order to achieve the Target Product Profile in the minimum number of iterations.
- ▶ Disease biology relevant and mechanism-driven assays and models applied in a rationale and efficient way such as translational biology strategies for the early identification of biomarkers using patient-derived iPSCs, cells and tissues combined with omics approaches.
- ▶ Deep understanding of PK/PD relationship and human dose prediction as early as possible.
- ▶ Focus on embedding development quality and de-risking during lead optimisation, to ensure smooth transition into development and reduced risk of downstream attrition and delay.
- ▶ Fully transparent resourcing with complete flexibility depending on project progress.
- ▶ Expert project strategy and leadership across all critical functions to drive forward achieving the desired outcomes.

Drug discovery and development always requires elements of problem-solving and innovation to achieve success. We believe connected and experienced individuals working in highly effective teams, maximize the chances of success and the speed with which the breakthroughs are conceived and realized. By working with Evotec, your project is in the safest hands and has the best chance of success for you and for the patients you are striving to help.
